Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05179603
Title A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi

Hodgkin's lymphoma

diffuse large B-cell lymphoma



Pembrolizumab + THOR-707

Age Groups: adult | child | senior
Covered Countries ESP

No variant requirements are available.